108 related articles for article (PubMed ID: 2310207)
21. Increased plasma histamine level in eosinophilic fasciitis.
Falanga V; Soter NA; Kerdel FA
Arch Dermatol; 1989 Jun; 125(6):805-8. PubMed ID: 2730101
[TBL] [Abstract][Full Text] [Related]
22. Increased expression of basic fibroblast growth factor in skin of patients with systemic sclerosis.
Lawrence A; Khanna D; Misra R; Aggarwal A
Dermatol Online J; 2006 Jan; 12(1):2. PubMed ID: 16638370
[TBL] [Abstract][Full Text] [Related]
23. Mast cell numbers in diffuse scleroderma.
Nishioka K; Kobayashi Y; Katayama I; Takijiri C
Arch Dermatol; 1987 Feb; 123(2):205-8. PubMed ID: 3813593
[TBL] [Abstract][Full Text] [Related]
24. Clinical associations of fibroblast growth promoting factor in scleroderma.
Potter SR; Bienenstock J; Lee P; Wilkinson S; Buchanan WW
J Rheumatol; 1984 Feb; 11(1):43-7. PubMed ID: 6699832
[TBL] [Abstract][Full Text] [Related]
25. Serum soluble CTLA-4 levels are increased in diffuse cutaneous systemic sclerosis.
Sato S; Fujimoto M; Hasegawa M; Komura K; Yanaba K; Hayakawa I; Matsushita T; Takehara K
Rheumatology (Oxford); 2004 Oct; 43(10):1261-6. PubMed ID: 15266059
[TBL] [Abstract][Full Text] [Related]
26. Elevated serum tumor necrosis factor-alpha levels in patients with systemic sclerosis: association with pulmonary fibrosis.
Hasegawa M; Fujimoto M; Kikuchi K; Takehara K
J Rheumatol; 1997 Apr; 24(4):663-5. PubMed ID: 9101498
[TBL] [Abstract][Full Text] [Related]
27. Correlation of endostatin and tissue inhibitor of metalloproteinases 2 (TIMP2) serum levels with cardiovascular involvement in systemic sclerosis patients.
Dziankowska-Bartkowiak B; Waszczykowska E; Zalewska A; Sysa-Jedrzejowska A
Mediators Inflamm; 2005 Aug; 2005(3):144-9. PubMed ID: 16106100
[TBL] [Abstract][Full Text] [Related]
28. Serum CXCL16 concentrations correlate with the extent of skin sclerosis in patients with systemic sclerosis.
Yanaba K; Muroi E; Yoshizaki A; Hara T; Ogawa F; Shimizu K; Yozaki M; Hasegawa M; Fujimoto M; Takehara K; Sato S
J Rheumatol; 2009 Sep; 36(9):1917-23. PubMed ID: 19605674
[TBL] [Abstract][Full Text] [Related]
29. Increased levels of type I and III collagen and hyaluronan in scleroderma skin.
Søndergaard K; Heickendorff L; Risteli L; Risteli J; Zachariae H; Stengaard-Pedersen K; Deleuran B
Br J Dermatol; 1997 Jan; 136(1):47-53. PubMed ID: 9039294
[TBL] [Abstract][Full Text] [Related]
30. Different antibody patterns and different prognoses in patients with scleroderma with various extent of skin sclerosis.
Giordano M; Valentini G; Migliaresi S; Picillo U; Vatti M
J Rheumatol; 1986 Oct; 13(5):911-6. PubMed ID: 3546686
[TBL] [Abstract][Full Text] [Related]
31. Elevated serum APRIL levels in patients with systemic sclerosis: distinct profiles of systemic sclerosis categorized by APRIL and BAFF.
Matsushita T; Fujimoto M; Hasegawa M; Tanaka C; Kumada S; Ogawa F; Takehara K; Sato S
J Rheumatol; 2007 Oct; 34(10):2056-62. PubMed ID: 17896803
[TBL] [Abstract][Full Text] [Related]
32. Prolactin synthesis by lymphocytes from patients with systemic sclerosis.
Czuwara-Ladykowska J; Sicinska J; Olszewska M; Uhrynowska-Tyszkiewicz I; Rudnicka L
Biomed Pharmacother; 2006 May; 60(4):152-5. PubMed ID: 16632298
[TBL] [Abstract][Full Text] [Related]
33. Longitudinal analysis of serum cytokine concentrations in systemic sclerosis: association of interleukin 12 elevation with spontaneous regression of skin sclerosis.
Matsushita T; Hasegawa M; Hamaguchi Y; Takehara K; Sato S
J Rheumatol; 2006 Feb; 33(2):275-84. PubMed ID: 16465658
[TBL] [Abstract][Full Text] [Related]
34. [Pathogenesis of skin scleroderma--literature review].
Wojas-Pelc A; Lipko-Godlewska S
Przegl Lek; 2005; 62(5):310-3. PubMed ID: 16334538
[TBL] [Abstract][Full Text] [Related]
35. [Hemostasis in patients with systemic skin diseases].
Dovzhanskiĭ SI; Gerasimova MV; Rumiantseva EV
Vestn Dermatol Venerol; 1990; (10):37-9. PubMed ID: 2278192
[TBL] [Abstract][Full Text] [Related]
36. Systemic sclerosis. Case report and review of literature.
Dghoughi S; El Wady W; Taleb B
N Y State Dent J; 2010 Apr; 76(3):30-5. PubMed ID: 20533714
[TBL] [Abstract][Full Text] [Related]
37. [Growth factors in the pathogenesis of progressive systemic sclerosis].
Altomare GF; Polenghi MM; Pigatto PD; Florita S; Finzi AF
G Ital Dermatol Venereol; 1989 May; 124(5):187-92. PubMed ID: 2620917
[TBL] [Abstract][Full Text] [Related]
38. Cutaneous fibrinolytic activity in scleroderma.
Lotti T; Cerinic MM; Marmugi D; Fabbri P
Clin Exp Rheumatol; 1985; 3(3):249-53. PubMed ID: 4053443
[TBL] [Abstract][Full Text] [Related]
39. Serum prolidase activity in systemic sclerosis.
Celik A; Birer MN; Kilinc M
Clin Rheumatol; 2017 Aug; 36(8):1827-1832. PubMed ID: 28534076
[TBL] [Abstract][Full Text] [Related]
40. [Some aspects of systemic and localized (limited) sclerosis in children].
Kwiatkowska M; Rutkowska-Sak L; Zuber Z
Ann Acad Med Stetin; 2012; 58(1):23-7. PubMed ID: 23547390
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
